MedTrace Logo

Added Value of PET/CT in Assessment of Hepatocellular Malignancy Post Radiofrequency Ablation

NCT06960031 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2025-05-20

No results posted yet for this study

Summary

This study aims to assess the residual tumoral activity versus the well ablation of اepatocellular carcinoma (HCC) post radiofrequency ablation.

Conditions

  • PET/CT
  • Hepatocellular Malignancy
  • Radiofrequency Ablation

Interventions

OTHER

PET/CT technique

Hybrid positron emission tomography (PET) and computed tomography (CT) images will be performed using Philips hybrid system equipped with a 16 MDCT scanner. The whole-body PET images from the skull vault down to the knee will be performed using several bed positions acquisition, each bed is approximately 15cm axial filed with 4mm special resolution. The time of acquisition of the emission scan is about 2 min for each bed, with a total time range between 12 and 17 min.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-30
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06960031 on ClinicalTrials.gov